Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 143.00 151.00 170.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 457

Amryt Pharma Share Discussion Threads

Showing 5051 to 5066 of 7300 messages
Chat Pages: Latest  208  207  206  205  204  203  202  201  200  199  198  197  Older
DateSubjectAuthorDiscuss
18/9/2019
17:10
If only we could foretell the future, waterloo, but Bronxville makes a very good point on the lse bb: Bronxville Posts: 1,190 Price: 133.50 No Opinion Volume Today 16:02 Its going to be very interesting when volume starts kicking in here.. With the new money coming in AMYT will be in a good position to bid for FDA approved drugs for the European market
papillon
18/9/2019
16:34
As expected. Question is the CVR value as one would expect it to fall next week by a similar amount. Next 'wave' on Nasdaq?
waterloo01
18/9/2019
12:50
I see you've also posted this information, Kenwrong, on the lse bb and radar has replied thus: radar Posts: 2,973 Price: 130.00 No Opinion RE: Open Orphan to go the same way as Amryt? Today 08:22 Your question makes no sense the share price increase in amyt is for the most part a product of consolidation and not a value increase at this time. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> As usual radar is completely WRONG!! He really is a DOPE. He's obviously INNUMERATE. For radar's information AMYT was suspended back in May at 12.25p. CONSOLIDATION ONLY RAISED that to 73.5p. The current AMYT share price is 130p!!!!!! SO, radar, the AMYT share price has INCREASED BY 77% SINCE CONSOLIDATION. Unfortunately radar is a PEDLAR of FAKE news He obviously doesn't believe in FACTS!!!
papillon
18/9/2019
07:30
I put this on the Orphan thread - saw Mr Freil present at the Shares Magazine evening. Very strong business acumen and like Amryt the orphan model looks highly scaleble in the same way. He is also presneting at the Proactive event tonight in London. This podcast is also a good listen hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year
kenwrong
17/9/2019
12:26
Looking at the 3 year chart on the AMYT web site (it has been amended to a/c for the recent consolidation, unlike the long term ADVFN chart in the header) there appears to be significant resistance around the 130p level, alphabravo. Whether that resistance will hold, or be broken, I don't know as I can't predict share prices. If it is broken the next chart resistance is at 162p which corresponds to the 13th April 2017 & 26th May 2017 highs. If that 162p resistance is broken then it's "clear blue sky" for the AMYT share price There was a bullish double bottom formed on the AMYT chart last week when the share price rose above 106p. That double bottom gave a short term target price of circa 135p. The 73.5p closing low was on the 7th May this year. I'm guessing there might soon be a short term pullback for the AMYT sp, but that the recent AMYT chart is still very bullish, alphabravo.
papillon
17/9/2019
11:55
Slowly slowly catchy money Monkey
alphabravo321
17/9/2019
11:42
There were four big trades from Friday reported last night after the market closed.
papillon
17/9/2019
11:33
positivityNicholas 17 Sep '19 - 06:24 - 4908 of 4909 (Filtered) mdalos1 17 Sep '19 - 11:22 - 4909 of 4909 (Filtered)
papillon
17/9/2019
06:24
We don’t care what you are going to do with your handful of shares. It’s of mo interest to anyone. Do you think that by telling us your intentions we are all going to take note of the share guru that is you and follow your lead? Errr no
positivitynicholas
16/9/2019
17:05
Actually mdalos's target price of 133p before he sells is not a bad short term target based on the AMYT chart (not the long term AMYT chart shown in the header because ADVFN haven't taken a/c of the share consolidation). When it relisted AMYT went from the pre suspension price of 76p (allowing for consolidation) to close at 106p. An effective rise of 30p on the day. Chart theory says we could have a similar rise from the subsequent low of 103p. That would give a short term target of 133p. Will I follow mdalos's stated aim and sell at 133p? No, is the answer. Why? Because I agree with Mark Taub and Cathal Friel and believe, rightly, or wrongly, that this new AMYT/Aegerion combination is undervalued and will be significantly rerated when it lists on the Nasdaq sometime in Q4 2019. I agree, rightly, or wrongly, that Mark Taub & Cathal Friel are correct when they state that the new AMYT/Aegerion combination is significantly undervalued compared with it's prospective peer group on the Nasdaq based on the growth prospects of Aegerion's existing marketed drugs, Juxtapid/Lojuxta and Myalept, even without a contribution from AP101.
papillon
16/9/2019
16:04
Mdalos1 you are right. The CVR would be nice but if it doesn't happen so be it.
chica1
16/9/2019
13:33
What about free fall parachute jumping? Bog snorkelling? Feeding the Donkeys in a Sanctuary? The possibilities are endless!! I’m killing time on a train!
bazworth
16/9/2019
13:22
Papillon, I'm actually a fan the majority of the time but you need another hobby
tiananmen
16/9/2019
13:04
I posted that link on this bb last Thursday, dim2602. It was originally posted on the lse bb by Cadburyhill last Thursday. I've also mentioned Mark Taub's bullish opinion on both NVLN & AMYT more than once since then in my posts.
papillon
16/9/2019
12:30
I've added to my holding. I think there will be a material share price increase once AMRYT lists on Nasdaq. Although the link below is a buy recommendation for Novelion, which will hold around 8% of new Amryt shares after the deal, a lot of the information is relevant to Amryt shareholders too. Specifically, with the share price of new Amryt at £1.435 on Nasdaq listing this values the company at around $308m and enterprise value of around $458m. With 2018 sales of $137m this gives an EV/Sales ratio of 3.3. This compares very favourably with Amryts peer group listed here where the next lowest is 3.9 and the median of the group at 6. Amryt will hope that the Nasdaq listing goes well and there is a strong appetite for the shares, so I think they have deliberately factored in a discount to the listing price. If we assume that Amryt reaches the 3.9 ratio of the next lowest company in the peer group, that would give a share price of £1.70 Further, this is based on 2018 sales of $137m. The forecast for revenues in 2020 and 2021 are $200.7 and $314 respectively. If the EV/Sales ratio stays the same, this would imply a further increase in share price to £2.50 and £3.90 respectively. Ok, there are many of assumptions and estimates to get to these valuations and there could be a few hurdles along the way. But I like the risk/reward here and you currently get the CVR's worth up to £1.22 per share (but could be zero) in for free. As always DYOR https://seekingalpha.com/article/4290742-novelions-8_1-percent-stake-amryt-worth-1_50-share?dr=1
dlm2602
16/9/2019
12:26
So mdalos has sold all his shares then, bazworth? I didn't realise he had as many as 700+. I thought I was a small shareholder with my tiny 5k. LOL.
papillon
Chat Pages: Latest  208  207  206  205  204  203  202  201  200  199  198  197  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220702 18:01:56